AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (15.2 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Research Article | Open Access | Online First

Preparation of Bmi-1-siRNA Lipid Nanoparticles and Effects in Gastric Cancer

Hongzhang Yan1Hong Shen1Jinrong SiTu1Yingying Yang1Lingle Zhang1Kai Yang1,2,3( )
College of Fisheries and Life Science of Shanghai Ocean University, Shanghai 201306, China
Shanghai Jiao Tong University Affiliated Sixth People’s Hosptial, Shanghai 200233, China
Tongji Hospital of Tongji University, Shanghai 200065, China
Show Author Information

Graphical Abstract

Abstract

Malignant tumors remain a serious threat to human health and life and are a major public health problem globally. Herein, we designed and synthesized a novel nucleic acid nanomedicine AS1411-siRNA-LNPs (As@LNPs). Bmi-1 siRNA was coated with cationic liposomes, and a nucleic acid aptamer AS1411 with tumor cell-targeting ability was attached to the outermost layer of the liposomes. The average particle size of As@LNPs was 183 nm, and the polydispersion coefficient was 0.187. The encapsulation rate and drug loading of As@LNPs were 85% and 4.6%, respectively. The average electron mobility of the drug was 2.64 (μ/s)/(V/cm), and the zeta potential of As@LNPs was 33.79 ± 0.78 mV. The microstructure of the nanomedicine was evaluated via transmission electron microscopy. In vitro and in vivo experiments showed that As@LNPs significantly inhibited tumor growth and promoted tumor cell apoptosis. As@LNPs showed favorable biosafety with major tissues and organs, except glomerulus and renal epithelial cells.

References

[1]

P.J. Bates, D.A. Laber, D.M. Miller, et al. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Experimental and Molecular Pathology, 2009, 86(3): 151−164. https://doi.org/10.1016/j.yexmp.2009.01.004

[2]

C. Ritchie, B. Doran, K. Shah, et al. Combination of the aptamer AS1411 with paclitaxel or Ara-C produces synergistic inhibition of cancer cell growth. Cancer Research, 2007, 67(9_Supplement): 4818.

[3]

D. Jones, D. Dobinson, B. Doran. AS1411, a novel anti-nucleolin aptamer, shows synergy with other anti-cancer drugs in vitro and in vivo in AML models. Cancer Research, 2008, 68(9_Supplement): 5689.

[4]

A.V. Molofsky, S. He, M. Bydon, et al. Bmi-1 promotes neural stem cell self-renewal and neural development but not mouse growth and survival by repressing the p16Ink4a and p19Arf senescence pathways. Genes &Development, 2005, 19(12): 1432−1437. https://doi.org/10.1101/gad.1299505

[5]

N. Gautam, M. Kaur, S. Kaur. Structural assembly of polycomb group protein and insight of EZH2 in cancer progression: A review. Journal of Cancer Research and Therapeutics, 2021, 17(2): 311. https://doi.org/10.4103/jcrt.jcrt_1090_19

[6]

S. Dhawan, S.I. Tschen, A. Bhushan. Bmi-1 regulates the Ink4a/Arf locus to control pancreatic β-cell proliferation. Genes &Development, 2009, 23(8): 906−911. https://doi.org/10.1101/gad.1742609

[7]

J.J.L. Jacobs, B. Scheijen, J.-W. Voncken, et al. Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes &Development, 1999, 13(20): 2678−2690. https://doi.org/10.1101/gad.13.20.2678

[8]

S. Senthil Kumar, S. Sengupta, X.T. Zhu, et al. Diffuse intrinsic pontine glioma cells are vulnerable to mitotic abnormalities associated with BMI-1 modulation. Molecular Cancer Research, 2020, 18(11): 1711−1723. https://doi.org/10.1158/1541-7786.MCR-20-0099

[9]

Lu H, Sun H-Z, Li H, et al. The Clinicopathological Significance of Bmi-1 Expression in Pathogenesis and Progression of Gastric Carcinomas. Asian Pac J Cancer Prev, 2012, 13(7): 3437−3441. https://doi.org/10.7314/apjcp.2012.13.7.3437

[10]

Zhang X, Hua R, Wang X, et al. Identification of stem-like cells and clinical significance of candidate stem cell markers in gastric cancer. Oncotarget, 2019, 7(9): 9815−9831. https://doi.org/10.18632/oncotarget.6890

[11]
H. Rajabi, D. Kufe. MUC1-C oncoprotein integrates a program of EMT, epigenetic reprogramming and immune evasion in human carcinomas. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2017, 1868(1): 117–122.
[12]

L.B. Song, J. Li, W.T. Liao, et al. The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. The Journal of Clinical Investigation, 2009, 119(12): 3626−3636. https://doi.org/10.1172/JCI39374

[13]

K.H. Pietiläinen, K. Ismail, E. Järvinen, et al. DNA methylation and gene expression patterns in adipose tissue differ significantly within young adult monozygotic BMI-discordant twin pairs. International Journal of Obesity, 2016, 40(4): 654−661. https://doi.org/10.1038/ijo.2015.221

[14]

D.J.Y. Sun, X.J. Xu, X.Y. Fu, et al. Abstract P356: The temporal relationship between body mass index and DNA methylation: Longitudinal epigenome-wide association from the bogalusa heart study. Circulation, 2015, 131: AP356. https://doi.org/10.1161/circ.131.suppl_1.p356

[15]

A.A. Wang, S.M. Donovan, M. Teran-Garcia. Monocarboxylate transporter-1 genotype and breastfeeding status protect against elevated BMI in preschool aged Caucasian children. The FASEB Journal, 2012, 26(S1): 647.13. https://doi.org/10.1096/fasebj.26.1_supplement.647.13

[16]
E. Villamor, L.S. Rozek, A.A. Vanzomeren-dohm, et al. LINE-1 DNA methylation in Colombian school children is associated with birth weight and maternal BMI, and predicts physical growth. The FASEB Journal, 24(S1): 107.6.
[17]

Q.H. Dong, R. Kim, N.H. Park, et al. Abstract#5604: Bmi-1 protects human oral epithelial cells from ionizing radiation. Cancer Research, 2009, 69(9_Supplement): 5604.

[18]
S.K. Nair, D. Snyder, E. Gilboa. Cells treated with TAP-2 antisense oligonucleotides are potent antigen-presenting cells in vitro and in vivo. The Journal of Immunology, 1996, 156(5): 1772–1780.
[19]

L.A. Perkins, G.W. Fisher, M. Naganbabu, et al. High-content surface and total expression siRNA kinase library screen with VX-809 treatment reveals kinase targets that enhance F508del-CFTR rescue. Molecular Pharmaceutics, 2018, 15(3): 759−767. https://doi.org/10.1021/acs.molpharmaceut.7b00928

[20]

A. Arvey, E. Larsson, C. Sander, et al. Target mRNA abundance dilutes microRNA and siRNA activity. Molecular Systems Biology, 2010, 6: 363. https://doi.org/10.1038/msb.2010.24

[21]

J.L. Jiang, X.Y. Cui, Y.X. Huang, et al. Advances and prospects in integrated nano-oncology. Nano Biomedicine and Engineering, 2024, 16(2): 152−187. https://doi.org/10.26599/nbe.2024.9290060

[22]

T. Bose, D. Latawiec, P.P. Mondal, et al. Overview of nano-drugs characteristics for clinical application: The journey from the entry to the exit point. Journal of Nanoparticle Research, 2014, 16(8): 2527. https://doi.org/10.1007/s11051-014-2527-7

[23]

T. Boettler, B. Csernalabics, H. Salié, et al. SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis. Journal of Hepatology, 2022, 77(3): 653−659. https://doi.org/10.1016/j.jhep.2022.03.040

[24]

V. Colapicchioni, M. Tilio, L. Digiacomo, et al. Personalized liposome–protein corona in the blood of breast, gastric and pancreatic cancer patients. The International Journal of Biochemistry &Cell Biology, 2016, 75: 180−187. https://doi.org/10.1016/j.biocel.2015.09.002

[25]

T. Ding, J. Guan, M. Wang, et al. Natural IgM dominates in vivo performance of liposomes. J Control Release, 2020, 319: 371−381. https://doi.org/10.1016/j.jconrel.2020.01.018

[26]

A. Huang, S.J. Kennel, L. Huang. Immunoliposome labeling: a sensitive and specific method for cell surface labeling. Journal of Immunological Methods, 1981, 46: 141−151. https://doi.org/10.1016/0022-1759(81)90131-9

[27]

Z.X. Jiang, J. Guan, J. Qian, et al. Peptide ligand-mediated targeted drug delivery of nanomedicines. Biomaterials Science, 2019, 7(2): 461−471. https://doi.org/10.1039/c8bm01340c

[28]

W.L. Liu, A.Q. Ye, F.F. Han, et al. Advances and challenges in liposome digestion: Surface interaction, biological fate, and GIT modeling. Advances in Colloid and Interface Science, 2019, 263: 52−67. https://doi.org/10.1016/j.cis.2018.11.007

Nano Biomedicine and Engineering
Cite this article:
Yan H, Shen H, SiTu J, et al. Preparation of Bmi-1-siRNA Lipid Nanoparticles and Effects in Gastric Cancer. Nano Biomedicine and Engineering, 2024, https://doi.org/10.26599/NBE.2024.9290086

386

Views

53

Downloads

0

Crossref

0

Scopus

Altmetrics

Received: 02 April 2024
Revised: 06 May 2024
Accepted: 13 May 2024
Published: 04 July 2024
© The Author(s) 2024.

This is an open-access article distributed under  the  terms  of  the  Creative  Commons  Attribution  4.0 International  License (CC BY) (http://creativecommons.org/licenses/by/4.0/), which  permits  unrestricted  use,  distribution,  and reproduction in any medium, provided the original author and source are credited.

Return